Frontier Treatments
ADPKD fármaco en investigacións, gen and terapia de precisión, ingeniería celular y tisular, trasplante and replacement advances
⚠ Important Reminder
Most therapies on this page are not yet approved and remain in ensayo clínicos, preclínico estudios, or conceptual estadios. Do not attempt any experimental tratamiento on your own, including "terapia génica," "célula madre therapy," or "xenotrasplante" obtained from unofficial channels. All tratamiento decisions should be made jointly with your nefrólogo. This page is for understanding investigación progress only and is not medical advice.
The only disease-modifying drug approved worldwide to slow ADPKD progresión is tolvaptán (see Treatment Options). Everything else described here is investigational or emerging technology that may offer future options but is not available now.
Development estadio legend: ApprovedClinical trialPreclínicoConcept/early
1. Investigational Drug Pipeline
The following drugs attempt to slow crecimiento de quistes or protect función renal through different mechanisms. Except tolvaptán, none are approved for ADPKD.
Somatoestatina analogues (Octreotide / Lanreotide) Clinical trial
Octreotide-LAR and lanreotida are already used for other conditions (e.g., acromegaly, neuroendocrine tumors). In ADPKD:
- Octreotide: ALADIN trial series (3-year RCT, Lancet 2013; ALADIN 2, PLOS Med 2017/2018) showed inconsistent results — some slowing of riñón volume growth but limited función renal protection.
- Lanreotide: DIPAK-1 large randomized trial (309 pacientes, JAMA 2018) found no significant slowing of eGFR decline, with a need to monitor hígado infección de quiste riesgo.
Evidence level: B (RCTs exist but do not apoyo routine use) · Not approved for ADPKD.
miRNA-17 inhibitors (RGLS8429 / Farabursen) Clinical trial
- RGLS4326 (first genration): completed a proof-of-concept Fase 1 trial (NCT04536688).
- RGLS8429 (Farabursen, second genration): ongoing Fase 1/2 multiple-ascending-dose trial (NCT05521191); preliminary data show increased urinario PC1/PC2 and htTKV (height-adjusted volumen total renal) decline in some pacientes. FDA agreed to use htTKV as an accelerated approval surrogate endpoint; Fase 3 planned.
Evidence level: C (early ensayo clínico) · Sources: Regulus Therapeutics; Nature Communications 2019; ASN Kidney Week 2024.
PPAR-γ agonists (Pioglitazone) Clinical trial
Completed a single-center randomized, double-blind, placebo-controlled crossover Fase 1/2 seguridad trial (NCT02697617) in 18 non-diabetic ADPKD pacientes at 15 mg/day for 12 months; seguridad acceptable but sample too small to assess eficacia.
Evidence level: C (early seguridad trial) · Source: Blazer-Yost et al., Clinical Kidney Journal 2021.
HDAC6 inhibitors Preclínico
Tubacin, ACY-1215 and others are efectivo in modelo animals and in vitro but have not entered ensayo clínicos. A new oral selective HDAC6 inhibitor, GV-001, shows upregulation of PC1 and suppression of human crecimiento de quistes in preclínico estudios (Wu et al., J Med Chem 2025).
Evidence level: D (preclínico/animal and in vitro) · No ensayo en humanoss yet.
CDK inhibitors (Roscovitine) Preclínico
Effective only in PKD modelo animals (Bukanov et al., Nature 2006); no ADPKD human ensayo clínicos reported.
Evidence level: D (preclínico) · Source: Bukanov et al., Cell Cycle 2012.
Other targets: CFTR inhibitors / AMPK activators / mTOR inhibitors
- CFTR inhibitor GLPG2737 Trial (terminated): Fase 2a MANGROVE trial (NCT04578548) terminated early for lack of significant eficacia.
- Metformin (AMPK activator) Concept/early: efectivo in vitro/modelo animals; clínico evidencia limited and mostly observational. KDIGO 2025 does not recommend it as ADPKD-specific therapy.
- PXL770 (direct AMPK allosteric activator) Preclínico: received FDA orphan drug designation; no completed ADPKD ensayo clínico yet.
- mTOR inhibitors (everolimus / sirolimus) Tested but not approved: early/mid-estadio trials (NEJM 2010) failed to show función renal beneficio with notable adverse effects; KDIGO 2025 explicitly recommends against.
Evidence level: B-D · See the "Treatments not recommended" section of Treatment Options.
Drug pipeline overview
| Drug / target | Mechanism | Stage | Key result |
|---|---|---|---|
| Tolvaptan (receptor V2 antagonist) | Lower cAMP | Approved | Only approved drug to slow ADPKD progresión |
| Lanreotide / Octreotide | Inhibit cAMP | Clinical trial | DIPAK-1 did not significantly slow eGFR decline |
| RGLS8429 (anti-miR-17) | Upregulate PC1/PC2 | Fase 1/2 | Preliminary htTKV decline; Fase 3 planned |
| Pioglitazone (PPAR-γ) | Downregulate CFTR | Fase 1/2 | Safety acceptable; eficacia unverified |
| HDAC6 inhibitors | Lower cAMP/CFTR | Preclínico | Effective in animals/in vitro |
| Roscovitine (CDK inhibitor) | Arrest célula cycle | Preclínico | Animal models only |
| GLPG2737 (CFTR inhibitor) | Inhibit fluid secreción | Terminated | Fase 2a no significant eficacia |
| mTOR inhibitors | Inhibit proliferación | Not recommended | No función renal beneficio shown |
2. Gene and Precision Therapy
ADPKD is caused by mutacións in PKD1 or PKD2. Gene-level therapy is a frontier investigación direction, but none of the following is in routine clínico use.
Antisense oligonucleotides (ASO) Concept/early
anti-miR-17 ASOs (e.g., RGLS8429, see above) are in early ensayo clínicos. Other ASO strategies remain preclínico/IND-filing estadio. Arnatar's ART5 has been approved by China's NMPA for a first-in-ensayo en humanos.
Evidence level: D (early/preclínico) · Sources: JASN 2025 abstract ART5; NAR 2024.
Gene editing (CRISPR / base editing) Preclínico
Demonstrated only in mice and órganooides/human iPSC models to reduce quistes and restore PC1; not yet in ensayo en humanoss.
Evidence level: D (preclínico) · Sources: Cheng et al., JASN 2024 abstract; Cell and Bioscience 2024; Cell Stem Cell 2024.
Genotype-guided therapy (truncating vs non-truncating PKD1) Used for prognostic stratification
- Median ESRD onset age is about 55 years for PKD1 mutación truncantes versus about 67 years for non-truncating (Cornec-Le Gall et al., JASN 2013).
- Genotype information is incorporated into the PROPKD score for prognostic stratification and early tamizaje, but cannot yet guide drug choice.
Evidence level: B (used in clínico prognostic assessment) · Source: JCI Insight 2020 (DOI:10.1172/jci.insight.138724).
3. Cell and Tissue Engineering
Stem terapia celular Concept/early
Only a small Fase 1 seguridad trial (6 pacientes, Makhlough et al., Stem Cell Research & Therapy 2017) showed seguridad but no función renal improvement. Larger randomized trials are needed.
⚠ Commercial "célula madre cures for PKD" are mostly marketing without rigorous clínico evidencia. Do not receive such tratamientos at unlicensed clinics.
Evidence level: D (very early) · Source: Makhlough et al., 2017.
Kidney órganooidess Preclínico / investigación tool
Organoids are a investigación tool and drug-tamizaje platform, not a therapeutic product. They have already helped identify new drug candidates (e.g., Rho pathway inhibitors).
Evidence level: D (investigación platform) · Source: Tran et al., Nature Communications 2022.
Bioartificial riñón / nefrona progenitor células Preclínico / prototype
The Kidney Project (UCSF/Vanderbilt) bioreactor survived 7 days in a pig model (Kim et al., Nature Communications 2023). All approaches remain preclínico/engineering prototype estadio.
Evidence level: D (preclínico/prototype) · No long-term human ensayo clínicos yet.
4. Transplant and Replacement Advances
When eGFR progresses to the point of needing terapia de reemplazo renal, the standard options remain trasplante renal, hemodiálisis, and diálisis peritoneal. Below are frontier explorations.
Xenotrasplanteation (pig-to-human riñón) Experimental early clínico
- World's first living-recipient pig trasplante renal: Massachusetts General Hospital / eGenesis, March 2024 (Slayman case, NEJM 2025).
- Second case (with a mechanical heart pump): NYU Langone, April 2024 (Pisano case).
These are compassionate use / expanded access individual cases at an experimental early clínico estadio; long-term seguridad and survival are not yet established and far from routine.
Evidence level: C (case reports) · Sources: NEJM 2025 (DOI:10.1056/NEJMoa2412747); Xenotrasplanteation 2024.
Implantable artificial riñón (The Kidney Project) Prototype
In animal prototype testing; no long-term human ensayo clínicos yet.
Evidence level: D (prototype) · Sources: Kim et al., Nature Communications 2023; UCSF/Vanderbilt Kidney Project.
Wearable / portable diálisis advances Early trial
- Wearable Artificial Kidney (WAK, hemodiálisis): portable, sorbent-regenrated dialysate; an early feasibility ensayo en humanos (7 pacientes, 24 hours, Gura et al., JASN 2016/2017) was paused for technical issues and remains under engineering improvement.
- AWAK automated wearable diálisis peritoneal: portable, sorbent tidal PD; 2024 ASN reported 11 pacientes completing 7 days and 3 completing 30 days with acceptable seguridad; a pre-pivotal estudio is underway.
Evidence level: C (early feasibility) · Source: ASN Kidney Week 2024 abstract TH-OR69.
How to think rationally about frontier therapies
- "In investigación" does not mean "available now": drugs in ensayo clínicos may fail or take years to be approved.
- A case is not routine: breakthrough cases like xenotrasplante are scientific progress, but riesgos and long-term effects are unknown.
- Beware commercial marketing: be cautious of unofficial clinics promoting "terapia génica" or "célula madre cures" for PKD.
- Join legitimate ensayo clínicos: if you want to participate in investigación, discuss with your nefrólogo and use official channels such as ClinicalTrials.gov.
- Best action today: using approved therapies properly (tolvaptán, presión arterial control, estilo de vida management) and attending regular seguimientos is the most efectivo way to slow disease progresión right now.
⚠ Important Reminder
This page is for understanding ADPKD investigación progress only and is not medical advice. All tratamiento decisions should be made jointly by you and your nefrólogo. Do not attempt any experimental or unapproved tratamiento on your own.
Authoritative Institutions & Key Literature
The following are authoritative ADPKD guía bodies, investigación institutions, and examples of hospitals listed in publicly registered ADPKD ensayo clínicos. This list does not constitute a ranking or endorsement of any hospital or physician. Key frontier therapy and case papers are listed in the References section below.
Authoritative Guideline & Research Institutions
- KDIGO (Kidney Disease: Improving Global Outcomes) — the global authoritative body issuing the ADPKD evaluation and management guía (2025): KDIGO ADPKD guía
- PKD Foundation (U.S.) — paciente education and investigación advocacy órganoization: pkdcure.org
- Mayo Clinic — origin of the Mayo imaging classification for ADPKD; long-standing ADPKD investigación: Mayo Clinic PKD
- Yale School of Medicine — Somlo lab and others estudioing PKD1/PKD2 mechanism and ciliosry biology: Yale Nephrology investigación
- University of Alabama at Birmingham (UAB) — PKD investigación and translation center: UAB PKD Research
- University of Kansas Medical Center — NIH-funded PKD Research and Translation Core Center: KU PKD Research Center
- European PKD Initiative (EPKI) — European paciente advocacy and investigación órganoization: epki.eu
Chinese Tier-3 Hospitals Participating in ADPKD Clinical Trials (Examples)
The institutions below appear in publicly registered multicenter ADPKD ensayo clínicos and are listed as examples for care or consultation navigation only — not as a ranking or endorsement. Trial recruitment status changes over time; always verify current status via official hospital channels.
- Peking University First Hospital (Department of Nephrology) — lead site of the JMKX003142 Fase 2 ADPKD trial (NCT06800651 / CTR20250172)
- Shanghai Changzheng Hospital (Naval Medical University) — national lead site for the Venglustat trial (CTR20190456); triptolide formulation estudio in ADPKD (NCT02115659)
- West China Hospital, Sichuan University — participating site in multiple ADPKD multicenter trials
- First Affiliated Hospital, Sun Yat-sen University — ADPKD multicenter trial participant
- First Affiliated Hospital / Sir Run Run Shaw Hospital, Zhejiang University — ADPKD multicenter trial participants
- Chinese PLA General Hospital (First Medical Center) — ADPKD multicenter trial participant
- Xiangya Hospital, Central South University — ADPKD multicenter trial participant
- Peking Union Medical College Hospital — ADPKD multicenter trial participant
Note: If you wish to join a ensayo clínico, first discuss eligibility with your nefrólogo, then contact hospitals through official hospital channels. Never use unofficial brokers or paid "trial recruitment" channels.
References
- KDIGO 2025 Clinical Practice Guideline on the Evaluation and Management of ADPKD — KDIGO. Kidney International, 2025. DOI: 10.1016/j.kint.2024.07.010. View source
- DIPAK-1: Lanreotide in ADPKD — Meijer E, et al. JAMA, 2018. View source
- ALADIN: Octreotide in ADPKD (3-year RCT) — Caroli A, et al. Lancet, 2013. View source
- Anti-miR-17 oligonucleotide RGLS4326 in ADPKD — Lee EC, et al. Nature Communications, 2019. DOI: 10.1038/s41467-019-11983-y. View source
- RGLS8429 (Farabursen) Fase 1/2 — NCT05521191 — ClinicalTrials.gov. View source
- Pioglitazone in ADPKD (Fase 1/2 seguridad) — Blazer-Yost BL, et al. Clinical Kidney Journal, 2021. View source
- HDAC6 inhibition in ADPKD — Cebotaru L, et al. Kidney International, 2016. View source
- Roscovitine in PKD modelo animals — Bukanov NO, et al. Nature, 2006. View source
- GLPG2737 (CFTR inhibitor) MANGROVE Fase 2a — NCT04578548 — ClinicalTrials.gov. View source
- mTOR inhibitors (Everolimus) in ADPKD — Serra AL, et al. NEJM, 2010. View source
- PKD1 genotype and ESRD age (truncating vs non-truncating) — Cornec-Le Gall E, et al. JASN, 2013. View source
- Mesenchymal célula madre therapy in ADPKD (Fase 1) — Makhlough A, et al. Stem Cell Research & Therapy, 2017. View source
- ADPKD riñón órganooidess for drug tamizaje — Tran T, et al. Nature Communications, 2022. View source
- The Kidney Project bioreactor (pig model, 7-day survival) — Kim S, et al. Nature Communications, 2023. DOI: 10.1038/s41467-023-39888-2. View source
- First living-recipient pig trasplante renal (Slayman, MGH/eGenesis) — NEJM, 2025. DOI: 10.1056/NEJMoa2412747. View source
- Wearable artificial riñón (WAK) pilot — Gura V, et al. JASN, 2016. View source
Audience: adult ADPKD pacientes and families interested in investigación progress
Limitations: most frontier therapies are not approved; investigación progresses rapidly and some information may be outdated. Always rely on your nefrólogo's advice and the latest clínico guías. This page is not medical advice.